Comparison of chemokine and receptor gene expression between Wharton's jelly and bone marrow-derived mesenchymal stromal cells

Cytotherapy

Volumn 14, Issue 1, 2012, Pages 26-33

  Balasubramanian, Sudha ^a   Venugopal, Parvathy ^a   Sundarraj, Swathi ^a   Zakaria, Zubaidah ^b   Majumdar, Anish Sen ^a   Ta, Malancha ^c  

^a MANIPAL HOSPITAL   (India)

^b INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^c Manipal Academy of Higher Education   (India)

Author keywords

angiogenesis; chemokines; mesenchymal stromal cells; polymerase chain reaction array; receptors; Wharton's jelly

Indexed keywords

ARGININE; CHEMOKINE; GLUTAMIC ACID; GROWTH FACTOR; LEUCINE;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; BONE MARROW DERIVED MESENCHYMAL STROMAL CELL; CELL CULTURE; CELL HOMING; CELL MIGRATION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MESENCHYME CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; STROMA CELL; SUPERNATANT; UMBILICAL CORD; UPREGULATION; VASCULARIZATION; WHARTON JELLY;

EID: 83755188640     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.605119     Document Type: Article

References (31)

1. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119:2204-13. (Pubitemid 43960310)
2. Keyser KA, Beagles KE, Kiem HP. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant. 2007;16:555-62. (Pubitemid 351448291)
3. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-7. (Pubitemid 29282067)
4. Can A, Karahuseyinoglu S. Concise review. Human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells. 2007;11:2886-96.
5. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell. 2009;4:206-16.
6. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003;48:3464-74. (Pubitemid 37531912)
7. Ji JF, He BP, Dheen ST, Tay SS. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells. 2004;22:415-27. (Pubitemid 38736625)
8. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: Feasibility, cell migration, and body distribution. Circulation. 2003;108:863-8. (Pubitemid 37022130)
9. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20:419-27.
10. da Silva Meirelles L, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20: 419-27.
11. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells. Takeda et al (22) 2008;26:2287-99.
12. Weiss ML, Medicetty S, Bledsoe AR, Rachakatla RS, Choi M, Merchav S, et al. Human umbilical cord matrix stem cells: Preliminary characterization and effect of transplantation in a rodent model of Parkinson s disease. Stem Cells. 2006;24: 81-92.
13. Nekanti U, Mohanty L, Venugopal P, Balasubramanian S, Totey S, Ta M. Optimization and scale-up of Wharton s jelly-derived mesenchymal stem cells for clinical applications. Stem Cell Res. 2010;5:244-54.
14. Pal R, Hanwate M, Jan M, Totey S. Phenotypic and functional comparison of optimum culture condition for upscaling of bone marrow derived mesenchymal stem cells. J Tissue Eng Regen Med. 2009;3:163-74.
15. Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood. 2005;106:419-27. (Pubitemid 40981232)
16. Miyasaka M, Tanaka T. Lymphocyte traffi cking across high endothelial venules: Dogmas and enigmas. Nat Rev Immunol. 2004;4:360-70. (Pubitemid 38649278)
17. Strieter RM, Belperio JA, Burdick MD, Keane MP. CXC chemokines in angiogenesis relevant to chronic fi broproliferation. Curr Drug Targets Infl amm Allergy. 2005;4:23-6. (Pubitemid 40590030)
18. Bièche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L, et al. CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer. 2007;14:1039-52. (Pubitemid 351252435)
19. B arone F, Bombardieri M, Rosado MM, Morgan PR, Challacombe SJ, De Vita S, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjögren s syndrome and malt lymphoma: Association with reactive and malignant areas of lymphoid organization. J Immunol. 2008;180:5130-40.
20. Rupprecht TA, Plate A, Adam M, Wick M, Kastenbauer S, Schmidt C, et al. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fl uid in acute Lyme neuroborreliosis. J Neuroinfl ammation. 2009;6:42.
21. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, et al. The role of IL-1a in growth and autocrine expression of proangiogenic cytokine IL-8 in HNSCC. Clin Cancer Res. 2001;7:1812-20.
22. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 2009;460: 225-30.
23. Salcedo R, Young HA, Ponce ML, Ward JM, Kleinman HK, Murphy WJ, et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human ccr3 endothelial cells. J Immunol. 2001;166:7571-8. (Pubitemid 32525638)
24. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fi broblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol. 1997;17: 4015-23. (Pubitemid 27281877)
25. McFadden C, Morgan R, Rahangdale S, Green D, Yamasaki H, Center D, et al. Preferential migration of T regulatory cells induced by IL-16. J Immunol. 2007;179:6439-45.
26. Otero K, Vecchi A, Hirsch E, Kearley J, Vermi W, Del Prete A, et al. Nonredundant role of CCRL2 in lung dendritic cell traffi cking. Blood. 2010;116:2942-9.
27. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 2003;92:1098-106. (Pubitemid 36665855)
28. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: Preclinical study for treatment of peripheral arterial disease. Gene Ther. 2001;8:181-9. (Pubitemid 32186129)
29. Sezer O, Jakob C, Eucker J, Niemö l ler K, Gatz F, Wernecke, et al. Serum levels of the angiogenic cytokines basic fi broblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol. 2001;66:83-8. (Pubitemid 32154100)
30. Sobolewski K, Mal kowski A, Ba k owski E, Jaworski S. Wharton s jelly as a reservoir of peptide growth factors. Placenta. 2005;26:747-52. (Pubitemid 41535480)
31. Mal kowski A, Sobolewski K, Jaworski S, Ba k owski E. TGFbeta binding in human Wharton s jelly. Mol Cell Biochem. 2008;311:137-43.